Retrotransposons in Bone and Joint Diseases

Retrotransposons, including non-LTR elements such as LINEs and viral-derived endogenous retroviruses (ERVs), have long been dismissed as "junk DNA" and thought to be biochemically inert. However, emerging evidence suggests that the erosion of epigenetic control during aging and pathological states can lead to the awakening of these dormant genetic elements. Although the role of ERVs in cancer and neurodegeneration is increasingly recognized, their impact on musculoskeletal health has received little attention. This perspective review synthesizes recent and previous findings linking retrotransposon reactivation (particularly ERVs) to osteoarthritis (OA), rheumatoid arthritis (RA), and potentially osteoporosis. We discuss the epigenetic mechanisms that typically silence ERVs in musculoskeletal tissues, how these mechanisms fail in disease, and how the resulting reactivation leads to viral and molecular mimicry. These processes trigger both innate and adaptive immune responses, as well as cellular senescence. Finally, we highlight the therapeutic potential of targeting retrotransposon dysregulation, including its encoded proteins and nucleic acid-sensing pathways to treat chronic bone and joint disorders.